- New mechanisms of action, new trends, and data that emerged from EULAR 2023;
- New data on biosimilars from EULAR 2023;
- New data on anti-TNFs and real-world evidence with biosimilars; and
- New uses and data on adalimumab.
This educational activity has been supported by a medical education grant from VIATRIS.
The webinar is intended for healthcare professionals only.